Abstract
Dendritic cell-based anticancer immunotherapy is feasible, safe and results in the induction of tumor-specific immune responses, at least in a fraction of vaccinated patients. The concomitant activation of cytotoxic andhelper T cells, by loading DCs with peptides or electroporating them with the corresponding mRNAs, may further enhance vaccineinduced antitumor responses.
Original language | English (US) |
---|---|
Article number | e24440 |
Journal | OncoImmunology |
Volume | 2 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2013 |
Externally published | Yes |
Keywords
- Cancer immunotherapy
- Dendritic cell vaccination
- Helper T cells
- Metastatic melanoma
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology